Dr Anne-Christine Bay-Jensen brings a persistent drive for biomarker research and development to Nordic Bioscience A/S. She is fascinated by how biomarkers can provide value in easing translational science, drug development, and development of diagnostics for diseases like rheumatoid arthritis and osteoarthritis (OA). Anne’s interest in rheumatology was formed during her PhD studies at a Danish Hospital. Here, she built her strong knowledge of the pathogenesis of joint destruction and osteoarthritis disease progression.
Dr Anne Bay-Jensen is the Director of the ImmunoScience group at Nordic Bioscience – a group focused on developing novel biomarkers and testing them in clinical cohorts and translational models. Anne has been working in the OA field since 2003, when she started her PhD work, investigating cartilage changes as a function of OA. Although OA is not the only focus area of the ImmunoScience group, it is the area where Anne spends her research time. Anne’s primary interest is developing, testing, and validating markers that may subgroup patients based on their disease pathotype using soluble biomarkers reflecting tissue remodelling.